Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • CommuniquĂ© 53 Cover Image

    • Digital Therapeutics Landscape in Europe

    September 3, 2020 |  

    OPEN Health introduce an overview of regulatory and HTA developments for digital therapeutics in Europe focusing on Germany and the UK

    Digital Therapeutics Landscape in Europe: The Case of Germany and the UK

    The COVID-19 virus crisis has opened immense windows of opportunity in healthcare around the globe. One of the greatest opportunities is in digital health, and in particular, digital therapeutics (DTx). The need for continued medical care combined with social distancing has led to a spike in use of digital health tools worldwide.1 As the interest in and use of digital health has grown during this period, we anticipate that investments in digital health tools will continue to accelerate after the COVID-19 pandemic. When the COVID-19 outbreak started, millions of Chinese people turned to online doctors and online health tools1 to find the needed support for their health. While these developments could create new risks for privacy and data protection, they also represent an unprecedented opportunity to integrate industry 4.0 in healthcare for the benefit of patients.

    HIGHLIGHTS INCLUDE:
    • Opportunities and threats of digital therapeutics after COVID-19
    • Digital therapeutics landscape in the European Union
    • Review and comparison of the German and UK therapeutics landscape
    • Develop game-changing insights and competitive advantage on both a global and local scalepi

    Pink divider

    Download the white paper and learn how it’s happening now!

    Download the Paper- PMLiVE

    1. https://www.cnbc.com/2020/03/26/investments-in-digital-health-care-could-accelerate-after-coronavirus-credit-suisse-says.html

    This content was provided by OPEN Health

    Company Details

    OPEN Health

    OPEN Health

    Email
    Website

     Latest Content from  OPEN Health 

    OPEN Health attend EB World Congress—building on momentum and strength in numbers for epidermolysis bullosa

    Ben Speller shares his thoughts on the value of disease specific congresses

    OPEN Health use PR to support clinical trial recruitment

    International Clinical Trials Day finds clinical research in the spotlight like never before, with any news coming from the many studies into potential vaccines and treatments for SARS-CoV-2

    OPEN Health | European Congress on Rare Diseases (ECRD) 2020 in 60 seconds

    Gavin Jones, Director or Rare Disease, attends the congress to better understand the viewpoints of patient groups, health systems and payers

    OPEN Health attend day 2 of the ECRD2020 congress

    Gavin Jones is looking forward to sessions on innovation in advanced therapies and working towards equitable access.

    OPEN Health continued support for My Name’5 Doddie

    Charity fundraising for Motor Neuron Disease

    OPEN Health’s latest partnership with Rare Revolution Magazine

    Richard Jones introduces our Head of Health Psychology (Dr Sumira Riaz)

    OPEN Health CSR Report 2019

    Margot Hannah, Partner and Group Managing Director, and CSR lead at OPEN Health shares her thoughts on our latest report.

    OPEN Health at ECRD 2020

    Gavin Jones shares his thoughts on why congress is so important at this time and the key sessions he is looking forward to.

    OPEN Health discuss Global Community in Rare Disease

    Annie Rankin how we can work smarter with healthcare professionals

    OPEN Health Patient & Brand Communications highly commended finalist

    Shortlisted for Best Patient-Centric Approach for 2020 BOBI Awards.